Navigation Links
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Date:9/28/2007

e on what we believe is most critical to our future success -- building and advancing our pipeline."

Idenix currently has a non-nucleoside reverse transcriptase inhibitor (NNRTI), IDX899, for the treatment of HIV-1 that is being evaluated in phase I/II clinical testing. The company also has a comprehensive HCV discovery effort, comprised of a next-generation nucleoside polymerase inhibitor program, including IDX102 and IDX184, which are currently being evaluated in advanced preclinical testing, and HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs.

As a result of this restructuring, Idenix will incur between $5 million and $10 million in charges, primarily associated with one-time employee severance benefits and the write-off of certain assets. The company continues to expect to end 2007 with between $100 million and $110 million of cash, cash equivalents and marketable securities. Idenix estimates that this restructuring will result in savings of $40 million to $45 million on an annual basis.

"We have taken the steps necessary to streamline our organization and significantly reduce our expenses, while continuing to maintain the strength of our balance sheet," said Ronald Renaud, Jr., chief financial officer of Idenix. "We believe that we are now well-positioned to fund the advancement of our HIV and HCV discovery and development programs through 2009."

About Idenix/Novartis Collaboration

Idenix and Novartis Pharma AG established a collaboration in May 2003, at which point Novartis became a majority shareholder in Idenix. Currently, Novartis owns 56% of Idenix and has first right of refusal to Idenix's pipeline.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caus
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Front-face detection for high-concentrate, opaque or solid sample
4. Concentrated solar energy project wins Innovation Days prizes
5. Wisconsin stands at the center of scientific efforts to avert flu epidemics
6. Thompsons HHS legacy will include efforts to combat disease in Africa
7. Efforts to avoid friendly fire spawned ancestor of todays RFID
8. Manufacturing group says efforts led to big improvements
9. Madison grid computing efforts attack big research questions
10. Californian stem-cell efforts get new rules, attract lawsuits
11. Tech Council passes E-Learning efforts for Northern Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Massachusetts og SHENZHEN ... Tech Solutions Co., LTD, (BGI Tech), et datterselskab ... lancering af en ny human whole exome-sekvenseringstjeneste baseret ... Complete Genomics, højt anset i branchen for at ... højfølsom registrering af alle typer varianter, blev købt ...
(Date:7/22/2014)... Switzerland (PRWEB) July 22, 2014 ... are becoming an increasingly common sight. The rapid ... they are now well- established as a core ... low maintenance has made them the gas analyzer ... locations and conditions encountered in some processes have ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/21/2014)... 21, 2014 Lawrence Livermore ... Board (WIB) and Las Positas College (LPC) recently ... education and hands-on training for veterans, officials recently ... at Las Positas is designed to help ... engineering technician careers, and establishes a pipeline of ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... EUREKA Cluster dedicated to Smart Systems Integration, will be ... community on 14-17 June 2011 in Helsinki, Finland. The ... the creation of new consortia and new projects by ... discuss proposals. EURIPIDES, in close cooperation with VTT and ...
... 20, 2011 Harvest Technologies Corp. ( www.harvesttech.com ) ... sixty patient Heart Failure trial have been enrolled at ... trial is intended to evaluate the safety and clinical ... patients with Congestive Heart Failure (CHF) when using a ...
... full year as a public company, 2010, the biotechnology developer Divine ... and grew Q4 revenue by 88 percent over the previous Q4, ... $5.4 million, up by $1.9 million over the previous year. Fourth-quarter ... quarter of 2009. The maker of topical treatments for ...
Cached Biology Technology:Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE) 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 3
(Date:7/22/2014)... 14, 2014, by lightning from a weather system that moved ... fires: Stokes Fire, Gold Hikes Fire, French Creek Fire and ... now one larger fire. The fires are burning in timber ... acres in size. The present fire situation continues to ... firefighter safety is the priority on the Carlton Complex fires. ...
(Date:7/22/2014)... for Health Policy and Economics have linked tighter ... rates for schizophrenic individuals. , The study comes ... health actually save money, when other costs are ... an extra approval step before tests or treatments ... called prior authorization is intended to encourage ...
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
Breaking Biology News(10 mins):Are state Medicaid policies sentencing people with mental illnesses to prison? 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3
... (RFRH) systems with mulches were first researched in the ... water availability and to increase crop production. In RFRH ... bare or mulched furrows serve as planting zones. The ... in many parts of the world as a means ...
... of 34 institutions in 15 countries contributing to the measurements ... network, InGOS. , The network focuses on providing accurate information ... for a more vigorous climate action. In order to ... of greenhouse gas emissions is essential and not only ...
... article in the New England Journal of Medicine ... B was able to convert severe hemophilia to moderate or ... Methods Editor for Human Gene Therapy and ... represents an important milestone and "demonstrates unequivocally that gene therapy ...
Cached Biology News:Improved rainwater harvesting system promising 2DTU is participating in a European network on measurement of greenhouse gases 2Commentary and podcast on landmark gene therapy clinical trial for hemophilia B 2